Connective Tissue

Osteogenesis imperfecta type 3

0

studies recruiting now

as of 7 Sept 2026

5

studies registered in total

as of 7 Sept 2026

0

countries with a recruiting site

as of 7 Sept 2026

None

recruiting study posted to date

among recruiting studies

Recruiting trials

No recruiting trial found right now.

5 studies are registered for Osteogenesis imperfecta type 3, but none was recruiting as of 7 Sept 2026. Here is what is still worth doing.

Keep watching

Get an email when a new Osteogenesis imperfecta type 3 study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

About Osteogenesis imperfecta type 3

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (MBTPS2, COL1A1, COL1A2, P3H1, CRTAP, CREB3L1).

Treatments being studied

1 approved treatment and 12 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.

Approved: Teriparatide (Bonsity)
Phase 3Denosumab (Jubbonti)
Phase 3Risedronate Sodium (Actonel)
Phase 3Setrusumab
Phase 3Pamidronate Disodium (Aredia)
Phase 3Somatropin (Genotropin)
Phase 3Zoledronic Acid (Aclasta)
Phase 1Busulfan (Busilvex)
Phase 1Romosozumab (Evenity)

+ 4 more in development

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).